Psychiatric Disorders and Sleep Issues

Medical Clinics of North America

Volumn 98, Issue 5, 2014, Pages 1123-1143

  Sutton, Eliza L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Anxiety; Circadian rhythm disorders; Cognitive behavioral therapy for insomnia; Depression; Insomnia; Obstructive sleep apnea; Restless leg syndrome

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ESZOPICLONE; HYPERICUM PERFORATUM EXTRACT; MIRTAZAPINE; NEFAZODONE; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; ZOLPIDEM;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CIRCADIAN RHYTHM SLEEP DISORDER; COGNITIVE THERAPY; COMPULSION; DEPRESSION; HUMAN; IMPULSE CONTROL DISORDER; INSOMNIA; KINESIOTHERAPY; MENTAL DISEASE; MENTAL HEALTH; MONOTHERAPY; NARCOLEPSY; NEUROBIOLOGY; PARASOMNIA; PATHOLOGICAL GAMBLING; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SCHIZOPHRENIA; SLEEP DEPRIVATION; SLEEP DISORDERED BREATHING; SLEEP WALKING; SUICIDAL BEHAVIOR; WAKEFULNESS;

ANXIETY; CIRCADIAN RHYTHM DISORDERS; COGNITIVE-BEHAVIORAL THERAPY FOR INSOMNIA; DEPRESSION; INSOMNIA; OBSTRUCTIVE SLEEP APNEA; RESTLESS LEG SYNDROME;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BRAIN; CHRONOBIOLOGY DISORDERS; COGNITIVE THERAPY; CONTINUOUS POSITIVE AIRWAY PRESSURE; DOPAMINE AGONISTS; HUMANS; HYPNOTICS AND SEDATIVES; MENTAL DISORDERS; PATIENT COMPLIANCE; PHOTOTHERAPY; RESTLESS LEGS SYNDROME; SEROTONIN UPTAKE INHIBITORS; SLEEP; SLEEP DISORDERS;

EID: 84906061854     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2014.06.009     Document Type: Review

References (126)

1. Kessler R.C., Demler O., Frank R.G., et al. US prevalence and treatment of mental disorders, 1990 to 2003. NEngl J Med 2005, 352(24):2515-2523.
2. LeBlanc M., Mérette C., Savard J., et al. Incidence and risk factors of insomnia in a population-based sample. Sleep 2009, 32(8):1027-1037.
3. Sarsour K., Morin C.M., Foley K., et al. Association of insomnia severity and comorbid medical and psychiatric disorders in a health plan-based sample: insomnia severity and comorbidities. Sleep Med 2010, 11(1):69-74.
4. Ohayon M.M., Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. JPsychiatr Res 2003, 37(1):9-15.
5. Sivertsen B., Salo P., Mykletun A., et al. The bidirectional association between depression and insomnia: the HUNT study. Psychosom Med 2012, 74(7):758-765.
6. Baglioni C., Battagliese G., Feige B., et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. JAffect Disord 2011, 135(1-3):10-19.
7. Robillard R., Naismith S.L., Rogers N.L., et al. Delayed sleep phase in young people with unipolar or bipolar affective disorders. JAffect Disord 2013, 145(2):260-263.
8. Szentkiralyi A., Völzke H., Hoffmann W., et al. The relationship between depressive symptoms and restless legs syndrome in two prospective cohort studies. Psychosom Med 2013, 75(4):359-365.
9. Li Y., Mirzaei F., O'Reilly E.J., et al. Prospective study of restless legs syndrome and risk of depression in women. Am J Epidemiol 2012, 176(4):279-288.
10. Macey P.M., Woo M.A., Kumar R., et al. Relationship between obstructive sleep apnea severity and sleep, depression and anxiety symptoms in newly-diagnosed patients. PLoS One 2010, 5(4):e10211.
11. Ohayon M.M. The effects of breathing-related sleep disorders on mood disturbances in the general population. JClin Psychiatry 2003, 64(10):1195-1200.
12. Ohayon M.M. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med 2013, 14(6):488-492.
13. Ohayon M.M., Zulley J., Guilleminault C., et al. Prevalence and pathologic associations of sleep paralysis in the general population. Neurology 1999, 52(6):1194-1200.
14. Ohayon M.M., Mahowald M.W., Dauvilliers Y., et al. Prevalence and comorbidity of nocturnal wandering in the U.S. adult general population. Neurology 2012, 78(20):1583-1589.
15. Marcks B.A., Weisberg R.B., Edelen M.O., et al. The relationship between sleep disturbance and the course of anxiety disorders in primary care patients. Psychiatry Res 2010, 178(3):487-492.
16. Paterson J.L., Reynolds A.C., Ferguson S.A., et al. Sleep and obsessive-compulsive disorder (OCD). Sleep Med Rev 2013, 17(6):465-474.
17. Neckelmann D., Mykletun A., Dahl A.A. Chronic insomnia as a risk factor for developing anxiety and depression. Sleep 2007, 30(7):873-880.
18. Mukhopadhyay S., Fineberg N.A., Drummond L.M., et al. Delayed sleep phase in severe obsessive-compulsive disorder: a systematic case-report survey. CNS Spectr 2008, 13(5):406-413.
19. Sharpless B.A., Barber J.P. Lifetime prevalence rates of sleep paralysis: a systematic review. Sleep Med Rev 2011, 15(5):311-315.
20. Bell C.C., Dixie-Bell D.D., Thompson B. Further studies on the prevalence of isolated sleep paralysis in black subjects. JNatl Med Assoc 1986, 78(7):649-659.
21. Ohayon M.M., Shapiro C.M. Sleep disturbances and psychiatric disorders associated with posttraumatic stress disorder in the general population. Compr Psychiatry 2000, 41(6):469-478.
22. van Liempt S. Sleep disturbances and PTSD: a perpetual circle?. Eur J Psychotraumatol 2012, 3. 10.3402/ejpt.v3i0.19142.
23. Sharpless B.A., McCarthy K.S., Chambless D.L., et al. Isolated sleep paralysis and fearful isolated sleep paralysis in outpatients with panic attacks. JClin Psychol 2010, 66(12):1292-1306.
24. Wulff K., Dijk D.J., Middleton B., et al. Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry 2012, 200(4):308-316.
25. Perez-Lloret S., Rey M.V., Bondon-Guitton E., French Association of Regional Pharmacovigilance Centers, et al. Drugs associated with restless legs syndrome: a case/noncase study in the French Pharmacovigilance Database. JClin Psychopharmacol 2012, 32(6):824-827.
26. Rittmannsberger H., Werl R. Restless legs syndrome induced by quetiapine: report of seven cases and review of the literature. Int J Neuropsychopharmacol 2013, 16(6):1427-1431.
27. Rishi M.A., Shetty M., Wolff A., et al. Atypical antipsychotic medications are independently associated with severe obstructive sleep apnea. Clin Neuropharmacol 2010, 33(3):109-113.
28. Huang Y.S., Guilleminault C., Chen C.H., et al. Narcolepsy-cataplexy and schizophrenia in adolescents. Sleep Med 2014, 15(1):15-22.
29. Kishi Y., Konishi S., Koizumi S., et al. Schizophrenia and narcolepsy: a review with a case report. Psychiatry Clin Neurosci 2004, 58(2):117-124.
30. Seeman M.V. Sleepwalking, a possible side effect of antipsychotic medication. Psychiatr Q 2011, 82(1):59-67.
31. Kodaka M., Matsumoto T., Katsumata Y., et al. Suicide risk among individuals with sleep disturbances in Japan: a case-control psychological autopsy study. Sleep Med 2014, 15(4):430-435.
32. McCall W.V., Blocker J.N., D'Agostino R., et al. Insomnia severity is an indicator of suicidal ideation during a depression clinical trial. Sleep Med 2010, 11(9):822-827.
33. Malik S., Kanwar A., Sim L.A., et al. The association between sleep disturbances and suicidal behaviors in patients with psychiatric diagnoses: a systematic review and meta-analysis. Syst Rev 2014, 3:18. 10.1186/2046-4053-3-18.
34. Baird A.L., Coogan A.N., Siddiqui A., et al. Adult attention-deficit hyperactivity disorder is associated with alterations in circadian rhythms at the behavioural, endocrine and molecular levels. Mol Psychiatry 2012, 17(10):988-995.
35. Cortese S., Konofal E., Lecendreux M., et al. Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Sleep 2005, 28(8):1007-1013.
36. Sedky K., Bennett D.S., Carvalho K.S. Attention deficit hyperactivity disorder and sleep disordered breathing in pediatric populations: a meta-analysis. Sleep Med Rev 2014, 18(4):349-356. pii:S1087-0792(13) 00132-9.
37. Oǧuztürk Ö., Ekici M., Çimen D., et al. Attention deficit/hyperactivity disorder in adults with sleep apnea. JClin Psychol Med Settings 2013, 20(2):234-239.
38. Voon V., Schoerling A., Wenzel S., et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol 2011, 11:117.
39. Carney C.E., Segal Z.V., Edinger J.D., et al. Acomparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. JClin Psychiatry 2007, 68(2):254-260.
40. Manber R., Bernert R.A., Suh S., et al. CBT for insomnia in patients with high and low depressive symptom severity: adherence and clinical outcomes. JClin Sleep Med 2011, 7(6):645-652.
41. Manber R., Edinger J.D., Gress J.L., et al. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep 2008, 31(4):489-495.
42. Rethorst C.D., Sunderajan P., Greer T.L., et al. Does exercise improve self-reported sleep quality in non-remitted major depressive disorder?. Psychol Med 2013, 43(4):699-709.
43. Combs K., Smith P.J., Sherwood A., et al. Impact of sleep complaints and depression outcomes among participants in the standard medical intervention and long-term exercise study of exercise and pharmacotherapy for depression. JNerv Ment Dis 2014, 202(2):167-171.
44. McClintock S.M., Husain M.M., Wisniewski S.R., et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. JClin Psychopharmacol 2011, 31(2):180-186.
45. Fabbri C., Marsano A., Balestri M., et al. Clinical features and drug induced side effects in early versus late antidepressant responders. JPsychiatr Res 2013, 47(10):1309-1318.
46. Papakostas G.I., Nutt D.J., Hallett L.A., et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006, 60(12):1350-1355.
47. Asnis G.M., Chakraburtty A., DuBoff E.A., et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. JClin Psychiatry 1999, 60(10):668-676.
48. Fava M., Asnis G.M., Shrivastava R.K., et al. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. JClin Psychiatry 2011, 72(7):914-928.
49. US Food and Drug Administration. FDA Drug Safety Communication: risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). 2013. Available at: Accessed May 18, 2014. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM335007.pdf.
50. Fava M., McCall W.V., Krystal A., et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006, 59(11):1052-1060.
51. Krystal A., Fava M., Rubens R., et al. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. JClin Sleep Med 2007, 3(1):48-55.
52. Hojo Y., Echizenya M., Ohkubo T., et al. Drug interaction between St John's wort and zolpidem in healthy subjects. JClin Pharm Ther 2011, 36(6):711-715.
53. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose. 2014. Available at: Accessed May 18, 2014. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM397277.pdf.
54. Garakani A., Martinez J.M., Marcus S., et al. Arandomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008, 23(5):269-275.
55. Anderson S.L., Vande Griend J.P. Quetiapine for insomnia: a review of the literature. Am J Health Syst Pharm 2014, 71(5):394-402.
56. Hermes E.D., Sernyak M., Rosenheck R. Use of second-generation antipsychotic agents for sleep and sedation: a provider survey. Sleep 2013, 36(4):597-600.
57. Jacobsen F.M. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. JClin Psychiatry 1990, 51(7):298-302.
58. Nierenberg A.A., Adler L.A., Peselow E., et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994, 151(7):1069-1072.
59. Fagiolini A., Comandini A., Catena Dell'Osso M., et al. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs 2012, 26(12):1033-1049.
60. Dolder C.R., Nelson M.H., Iler C.A. The effects of mirtazapine on sleep in patients with major depressive disorder. Ann Clin Psychiatry 2012, 24(3):215-224.
61. Watanabe N., Omori I.M., Nakagawa A., et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2011, (12). CD006528. 10.1002/14651858.CD006528.pub2.
62. Hicks J.A., Argyropoulos S.V., Rich A.S., et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 2002, 180:528-535.
63. Rush A.J., Armitage R., Gillin J.C., et al. Comparative effects of nefazodone and fluoxetine in outpatients with major depressive disorder. Biol Psychiatry 1998, 44(1):3-14.
64. Bayard M., Bailey B., Acharya D., et al. Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 2011, 24(4):422-428.
65. Rottach K.G., Schaner B.M., Kirch M.H., et al. Restless legs syndrome as side effect of second generation antidepressants. JPsychiatr Res 2008, 43(1):70-75.
66. Ohayon M.M., Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. JPsychosom Res 2002, 53(1):547-554.
67. Young W.B., Piovesan E.J., Biglan K.M. Restless legs syndrome and drug-induced akathisia in headache patients. CNS Spectr 2003, 8(6):450-456.
68. Tamanna S., Ullah M.I., Pope C.R., et al. Quetiapine-induced sleep-related eating disorder-like behavior: a case series. JMed Case Rep 2012, 6(1):380.
69. Kahn-Greene E.T., Killgore D.B., Kamimori G.H., et al. The effects of sleep deprivation on symptoms of psychopathology in healthy adults. Sleep Med 2007, 8(3):215-221.
70. Minkel J., Htaik O., Banks S., et al. Emotional expressiveness in sleep-deprived healthy adults. Behav Sleep Med 2011, 9(1):5-14.
71. van der Helm E., Gujar N., Walker M.P. Sleep deprivation impairs the accurate recognition of human emotions. Sleep 2010, 33(3):335-342.
72. Benca R.M., Obermeyer W.H., Thisted R.A., et al. Sleep and psychiatric disorders. A meta-analysis. Arch Gen Psychiatry 1992, 49(8):651-668. [discussion: 669-70].
73. Nollet M., Leman S. Role of orexin in the pathophysiology of depression: potential for pharmacological intervention. CNS Drugs 2013, 27(6):411-422.
74. Partonen T. Clock gene variants in mood and anxiety disorders. JNeural Transm 2012, 119(10):1133-1145.
75. McClung C.A. Role for the Clock gene in bipolar disorder. Cold Spring Harb Symp Quant Biol 2007, 72:637-644.
76. Li J.Z., Bunney B.G., Meng F., et al. Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. Proc Natl Acad Sci USA 2013, 110(24):9950-9955.
77. Merlo Pich E., Melotto S. Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use. Front Neurosci 2014, 8:26. eCollection 2014. 10.3389/fnins.2014.00026.
78. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2013, American Psychiatric Publishing, Arlington (VA). 5th edition.
79. American Academy of Sleep Medicine International classification of sleep disorders 2014, American Academy of Sleep Medicine, Darien (IL). 3rd edition.
80. Sutton E.L. Insomnia. Med Clin North Am 2014, 98(3):565-581.
81. Morin C.M., Bootzin R.R., Buysse D.J., et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep 2006, 29(11):1398-1414.
82. Mitchell M.D., Gehrman P., Perlis M., et al. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract 2012, 13:40. 10.1186/1471-2296-13-40.
83. Sánchez-Ortuño M.M., Edinger J.D. Cognitive-behavioral therapy for the management of insomnia comorbid with mental disorders. Curr Psychiatry Rep 2012, 14(5):519-528.
84. Wagley J.N., Rybarczyk B., Nay W.T., et al. Effectiveness of abbreviated CBT for insomnia in psychiatric outpatients: sleep and depression outcomes. JClin Psychol 2013, 69(10):1043-1055.
85. Mack L.J., Rybarczyk B.D. Behavioral treatment of insomnia: a proposal for a stepped-care approach to promote public health. Nat Sci Sleep 2011, 3:87-99.
86. Vincent N., Walsh K. Stepped care for insomnia: an evaluation of implementation in routine practice. JClin Sleep Med 2013, 9(3):227-234.
87. Ford D.E., Kamerow D.B. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?. JAMA 1989, 262(11):1479-1484.
88. Kamphuis J., Dijk D.J., Spreen M., et al. The relation between poor sleep, impulsivity and aggression in forensic psychiatric patients. Physiol Behav 2014, 123:168-173.
89. Roberts R.E., Duong H.T. The prospective association between sleep deprivation and depression among adolescents. Sleep 2014, 37(2):239-244.
90. Wu J.C., Bunney W.E. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 1990, 147(1):14-21.
91. Wu J.C., Kelsoe J.R., Schachat C., et al. Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry 2009, 66(3):298-301.
92. Palagini L., Baglioni C., Ciapparelli A., et al. REM sleep dysregulation in depression: state of the art. Sleep Med Rev 2013, 17(5):377-390.
93. Pigeon W.R., Hegel M., Unützer J., et al. Is insomnia a perpetuating factor for late-life depression in the IMPACT cohort?. Sleep 2008, 31(4):481-488.
94. Chang P.P., Ford D.E., Mead L.A., et al. Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am J Epidemiol 1997, 146(2):105-114.
95. Nierenberg A.A., Husain M.M., Trivedi M.H., et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010, 40(1):41-50.
96. Perlis M.L., Giles D.E., Buysse D.J., et al. Self-reported sleep disturbance as a prodromal symptom in recurrent depression. JAffect Disord 1997, 42(2-3):209-212.
97. Gulec M., Selvi Y., Boysan M., et al. Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: a 52-week follow-up study. JAffect Disord 2011, 134(1-3):257-265.
98. Tuunainen A., Kripke D.F., Endo T. Light therapy for non-seasonal depression. Cochrane Database Syst Rev 2004, (2). CD004050.
99. Pail G., Huf W., Pjrek E., et al. Bright-light therapy in the treatment of mood disorders. Neuropsychobiology 2011, 64(3):152-162.
100. Benes H., Walters A.S., Allen R.P., et al. Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord 2007, 22(Suppl 18):S401-S408.
101. Benes H., Mattern W., Peglau I., et al. Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. JNeurol 2011, 258(6):1046-1054.
102. Launois C., Leu-Semenescu S., Brion A., et al. Major depression after withdrawing dopamine agonists in two patients with restless legs syndrome and impulse control disorders. Sleep Med 2013, 14(7):696.
103. Law M., Naughton M., Ho S., et al. Depression may reduce adherence during CPAP titration trial. JClin Sleep Med 2014, 10(2):163-169.
104. Giles T.L., Lasserson T.J., Smith B.J., et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006, (1). CD001106.
105. Gagnadoux F., Le Vaillant M., Goupil F., et al. Depressive symptoms before and after long term continuous positive airway pressure therapy in sleep apnea patients. Chest 2014, 10.1378/chest.13-2373.
106. Li C.T., Bai Y.M., Lee Y.C., et al. High dosage of hypnotics predicts subsequent sleep-related breathing disorders and is associated with worse outcomes for depression. Sleep 2014, 37(4):803-809.
107. Dauvilliers Y., Paquereau J., Bastuji H., et al. Psychological health in central hypersomnias: the French Harmony study. JNeurol Neurosurg Psychiatry 2009, 80(6):636-641.
108. Norell-Clarke A., Jansson-Fröjmark M., Tillfors M., et al. Cognitive processes and their association with persistence and remission of insomnia: findings from a longitudinal study in the general population. Behav Res Ther 2014, 54:38-48.
109. Fava M., Asnis G.M., Shrivastava R., et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. JClin Psychopharmacol 2009, 29(3):222-230.
110. Pollack M., Kinrys G., Krystal A., et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008, 65(5):551-562.
111. Bélanger L., Morin C.M., Langlois F., et al. Insomnia and generalized anxiety disorder: effects of cognitive behavior therapy for GAD on insomnia symptoms. JAnxiety Disord 2004, 18(4):561-571.
112. Maher M.J., Rego S.A., Asnis G.M. Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs 2006, 20(7):567-590.
113. El-Solh A.A., Ayyar L., Akinnusi M., et al. Positive airway pressure adherence in veterans with posttraumatic stress disorder. Sleep 2010, 33(11):1495-1500.
114. Otto M.W., Simon N.M., Powers M., et al. Rates of isolated sleep paralysis in outpatients with anxiety disorders. JAnxiety Disord 2006, 20(5):687-693.
115. Kalucy M.J., Grunstein R., Lambert T., et al. Obstructive sleep apnoea and schizophrenia-a research agenda. Sleep Med Rev 2013, 17(5):357-365.
116. Wamsley E., Donjacour C.E., Scammell T.E., et al. Delusional confusion of dreaming and reality in narcolepsy. Sleep 2014, 37(2):419-422.
117. Adler L.A., Goodman D., Weisler R., et al. Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. Behav Brain Funct 2009, 5:34.
118. Wietecha L.A., Ruff D.D., Allen A.J., et al. Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. JClin Psychiatry 2013, 74(12):1217-1223.
119. Surman C.B., Roth T. Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials. JClin Psychiatry 2011, 72(7):903-908.
120. Boonstra A.M., Kooij J.J., Oosterlaan J., et al. Hyperactive night and day? Actigraphy studies in adult ADHD: a baseline comparison and the effect of methylphenidate. Sleep 2007, 30(4):433-442.
121. England S.J., Picchietti D.L., Couvadelli B.V., et al. L-Dopa improves restless legs syndrome and periodic limb movements in sleep but not attention-deficit-hyperactivity disorder in a double-blind trial in children. Sleep Med 2011, 12(5):471-477.
122. Cortese S., Angriman M., Lecendreux M., et al. Iron and attention deficit/hyperactivity disorder: what is the empirical evidence so far? A systematic review of the literature. Expert Rev Neurother 2012, 12(10):1227-1240.
123. Maher A.R., Maglione M., Bagley S., et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011, 306(12):1359-1369.
124. Swanson L.M., Flynn H., Adams-Mundy J.D., et al. An open pilot of cognitive-behavioral therapy for insomnia in women with postpartum depression. Behav Sleep Med 2013, 11(4):297-307.
125. Arnedt J.T., Conroy D.A., Armitage R., et al. Cognitive-behavioral therapy for insomnia in alcohol dependent patients: a randomized controlled pilot trial. Behav Res Ther 2011, 49(4):227-233.
126. Talbot L.S., Maguen S., Metzler T.J., et al. Cognitive behavioral therapy for insomnia in posttraumatic stress disorder: a randomized controlled trial. Sleep 2014, 37(2):327-341.